 Connection
Michael Mitchell to Immunotherapy
This is a "connection" page, showing publications Michael Mitchell has written about Immunotherapy.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
4.442 |
|
|
|
-
Shi Q, Gong N, Wang J, Palanki R, Zheng Q, Alameh MG, Dwivedi G, Davis B, Melamed J, Luo Z, Xu J, Figueroa-Espada CG, Xue L, Zeng Y, Han X, Kim D, Chen Q, Yamagata H, Geisler HC, El-Mayta R, Yoon IC, Weissman D, Mitchell MJ. Prodrug-tethered lipid nanoparticles for synergistic messenger RNA cancer immunotherapy. Nat Nanotechnol. 2026 Mar; 21(3):430-442.
Score: 0.669
-
Wang J, Huang X, Shi Q, Swingle KL, Hamilton AG, Gong N, Mitchell MJ. Drug-loaded bispecific T cell nanoengager overcomes T cell exhaustion for potent cancer immunotherapy. Proc Natl Acad Sci U S A. 2025 Nov 11; 122(45):e2409564122.
Score: 0.652
-
Kim EH, Teerdhala SV, Padilla MS, Joseph RA, Li JJ, Haley RM, Mitchell MJ. Lipid nanoparticle-mediated RNA delivery for immune cell modulation. Eur J Immunol. 2024 12; 54(12):e2451008.
Score: 0.603
-
El-Mayta R, Zhang Z, Hamilton AG, Mitchell MJ. Delivery technologies to engineer natural killer cells for cancer immunotherapy. Cancer Gene Ther. 2021 09; 28(9):947-959.
Score: 0.476
-
Gong N, Sheppard NC, Billingsley MM, June CH, Mitchell MJ. Nanomaterials for T-cell cancer immunotherapy. Nat Nanotechnol. 2021 01; 16(1):25-36.
Score: 0.467
-
Mukalel AJ, Riley RS, Zhang R, Mitchell MJ. Nanoparticles for nucleic acid delivery: Applications in cancer immunotherapy. Cancer Lett. 2019 08 28; 458:102-112.
Score: 0.416
-
Riley RS, June CH, Langer R, Mitchell MJ. Delivery technologies for cancer immunotherapy. Nat Rev Drug Discov. 2019 03; 18(3):175-196.
Score: 0.410
-
Murray AM, Swingle KL, Mitchell MJ. Engineering Nanoparticles for Gynecologic Cancer Therapy. ACS Nano. 2025 Sep 02; 19(34):30758-30785.
Score: 0.161
-
Hamilton AG, Swingle KL, Thatte AS, Mukalel AJ, Safford HC, Billingsley MM, El-Mayta RD, Han X, Nachod BE, Joseph RA, Metzloff AE, Mitchell MJ. High-Throughput In Vivo Screening Identifies Differential Influences on mRNA Lipid Nanoparticle Immune Cell Delivery by Administration Route. ACS Nano. 2024 06 25; 18(25):16151-16165.
Score: 0.148
-
Metzloff AE, Padilla MS, Gong N, Billingsley MM, Han X, Merolle M, Mai D, Figueroa-Espada CG, Thatte AS, Haley RM, Mukalel AJ, Hamilton AG, Alameh MG, Weissman D, Sheppard NC, June CH, Mitchell MJ. Antigen Presenting Cell Mimetic Lipid Nanoparticles for Rapid mRNA CAR T Cell Cancer Immunotherapy. Adv Mater. 2024 06; 36(26):e2313226.
Score: 0.146
-
Gong N, Hamilton AG, Mitchell MJ. Exosome-disrupting peptides for cancer immunotherapy. Nat Mater. 2023 05; 22(5):530-531.
Score: 0.137
-
Zhang R, Billingsley MM, Mitchell MJ. Biomaterials for vaccine-based cancer immunotherapy. J Control Release. 2018 12 28; 292:256-276.
Score: 0.100
-
Gong N, Zhang Y, Teng X, Wang Y, Huo S, Qing G, Ni Q, Li X, Wang J, Ye X, Zhang T, Chen S, Wang Y, Yu J, Wang PC, Gan Y, Zhang J, Mitchell MJ, Li J, Liang XJ. Proton-driven transformable nanovaccine for cancer immunotherapy. Nat Nanotechnol. 2020 12; 15(12):1053-1064.
Score: 0.029
-
Oberli MA, Reichmuth AM, Dorkin JR, Mitchell MJ, Fenton OS, Jaklenec A, Anderson DG, Langer R, Blankschtein D. Lipid Nanoparticle Assisted mRNA Delivery for Potent Cancer Immunotherapy. Nano Lett. 2017 03 08; 17(3):1326-1335.
Score: 0.022
-
Smith MP, Spence KJ, Waters EL, Beresford-Webb R, Mitchell MJ, Cuttler J, Alhaq A, Brown SA, Savidge GF. Immune tolerance therapy for haemophilia A patients with acquired factor VIII alloantibodies: comprehensive analysis of experience at a single institution. Thromb Haemost. 1999 Jan; 81(1):35-8.
Score: 0.006
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|